Bionomics Limited (ASX: BNO) CEO & Managing Director Dr Deborah Rathjen presents at the ASX Spotlight Series in Hong Kong.Bionomics Limited (ASX: BNO) is a global company with a base in Adelaide, South Australia, but we also have a footprint in San Diego in the US and also in Europe.
We have major strategic partnerships with Merck & Co in the areas of Alzheimer's disease and pain and we are targeting some pretty large market opportunities here. Merck last year took a 4.5 per cent stake in Bionomics and it's wonderful to have them as owners of the company.
BNC210 is our lead drug and has been developed for the treatment of anxiety and depression. This is an area where there have been no new treatments in terms of mechanism of action for decades, and we feel we have a real game changer here.
